Litcius/Paper detail

LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)

Satoru Miura, Hiroshi Tanaka, T. Misumi, Hiroshige Yoshioka, Takayasu Kurata, Takaaki Tokito, T. Fukuhara, Yuki Sato, Yoshimasa Shiraishi, Shota Kusuhara, Shunsuke Teraoka, Terufumi Kato, Hidehito Horinouchi, Yuichi Takiguchi, Yasushi Goto, Kosuke Tanaka, Masaki Kanazu, Satoshi Ikeda, Eiki Ichihara, Hiroaki Okamoto

2023Annals of Oncology27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAfatinibEpidermal growth factor receptorOncologyLung cancerChemotherapyInternal medicineDermatologyCancer researchCancerGefitinibLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies
LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834) | Litcius